UCL Business and AGA Nanotech Ltd have concluded a licensing agreement for use of TIPS microparticle technology in directing the controlled delivery of antimicrobial agents in the healthcare setting. The licensing agreement represents the conclusion of a collaborative translational research program supported by the BRC, the UCL Translational Research Office and AGA Nanotech Ltd.
The technology was developed by Dr Richard Day, from the UCL Research Department of Metabolism and Experimental Therapeutics, and was one of the UCL translational research projects located in the laboratories at the Stevenage Bioscience Catalyst.
Dr Day said: "TIPS particle technology is an enabling platform with a variety of applications and our relationship with AGA Nanotech Ltd represents one of our first successful moves into product development. We continue to work with a number of interested parties across a number of application areas where the TIPS particle technology adds sustained and valuable benefits."
BRC Director Professor Bryan Williams said: “I am delighted that the BRC’s support and experience in bringing medical innovations to our patients has helped facilitate this exciting development; and look forward to seeing the TIPS microparticle technology in our clinical practice.”
Adrian Fellows, R&D Director, AGA Nanotech Ltd, said: "The collaboration with Dr Day's group has been highly productive, enabling the testing of ideas that will open up new business opportunities. AGA Nanotech Ltd believes that combining the TIPS delivery system with our own distinct antimicrobial expertise offers unique opportunities to replace conventional antibiotics, not only in healthcare and woundcare, but also in animal health and welfare."
The agreement was negotiated on behalf of the UCL by its technology commercialisation office, UCL Business. Cengiz Tarhan, Managing Director of UCL Business said: "TIPS has wide applicability and the development of a partnership between AGA Nanotech Ltd and UCL in this breakthrough area has been highly productive. The signing of this agreement represents a significant milestone and is a pivotal step in the progression of the TIPS particle technology into marketed products which support healthcare as they tackle the challenge of antimicrobial resistance."
Read further BRC coverage on TIPS microparticle technology here.
